HomeLatestQuoin (NASDAQ:QNRX) Shares on the Move as Company Announces First Clinical Site Open to Evaluate Netherton Syndrome Treatment
Quoin (NASDAQ:QNRX) Shares on the Move as Company Announces First Clinical Site Open to Evaluate Netherton Syndrome Treatment
July 06, 2022 at 1:28 pm - by Editor Investors Prism
In a significant step forward for rare disease treatment, Quoin Pharmaceuticals announced the opening of the first clinical site for its Netherton Syndrome study. The specialty pharma and biotech focused on rare and orphan diseases is well-positioned to potentially deliver the first FDA-approved treatment for the syndrome, a rare and devastating genetic disease with no cure or approved treatment, following on the heels of its recent Investigation New Drug (IND) application clearance from the FDA.
The clinical study will evaluate QRX003 to treat Netherton Syndrome, which leads to severe skin barrier defects, recurring infections, skin cancer, and pruritus among other medical conditions. The topical lotion is designed to create a more normalized skin shedding process leading to a stronger and more effective skin barrier. The randomized, double-blind, vehicle-controlled study will test two doses of QRX003, with opening of additional sites already in process and patient recruitment expected to begin shortly.
The lotion will be applied daily over a 12-week period to patients in contrast with a vehicle lotion. Several clinical endpoints will be assessed in the study.
In the company’s news release, Quoin CEO Dr. Michael Myers noted, “We are very pleased to announce another significant milestone in the development of QRX003 for this very underserved patient population. The opening of this first clinical site, with full Institutional Review Board approval, is testimony to the great work of our CRO, Therapeutics Inc. This is also an important step forward for our partners with whom we have established supply and distribution agreements for QRX003 in 60 countries, as it potentially advances the path to approval in their territories. Furthermore, many of these regions have early-access programs that the data from this study could potentially enable QRX003 to participate in, and be made available on a named patient basis prior to formal regulatory approval.”
Quoin has established relationships with dermatology experts and patient support foundations across the globe to promote extensive access for future marketing plus commercial leverage. With a focus on ensuring every patient, everywhere, can access approved products, the company is targeting regulatory approval in the United States and Europe in 2024, with sales anticipated to reach $262 billion by 2024.
Quoin shares were up more than 10% intra-day, bucking market trend.
“PCG” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PCG” engage in any activities that would require such registrations. “PCG” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.